ライフサイエンスコーパス: myalgia

1 stemic reactions were headache, malaise, and myalgia.

2 therapeutic index relative to statin-induced myalgia.

3 ctions included mild to moderate malaise and myalgia.

4 central pain processing in reserpine induced myalgia.

5 ausea and emesis, neuropathy, and arthralgia/myalgia.

6 e a potential analgesic therapy for ischemic myalgia.

7 pital with a persistent fever, headache, and myalgia.

8 iruses cause debilitating polyarthralgia and myalgia.

9 sarcopaenic and at increased risk of statin myalgia.

10 and fatigue and one developed arthralgia and myalgia.

11 e tested the association of the variant with myalgia.

12 ritis and sometimes prolonged arthralgia and myalgia.

13 ts were fatigue, rash, diarrhea, nausea, and myalgia.

14 liver function test elevation, fatigue, and myalgia.

15 bo, LPS caused headache, nausea, chills, and myalgias.

16 atistically significant (p < .05) except for myalgias.

17 ology as opposed to being arthralgias and/or myalgias.

18 on (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depres

19 The most frequent symptoms reported were myalgia (100%), fatigue (91%), fever (82%), headache (59

20 events were fatigue (29%), nausea (12%), and myalgia (11%).

21 ogic toxicities included neuropathies (26%), myalgia (13%), and fatigue (10%).

22 were nasal congestion (16% of patients) and myalgia (14%).

23 atorvastatin than placebo subjects developed myalgia (19 versus 10; P=0.05).

24 Both vaccines were well-tolerated, with myalgia (19%), malaise (14%), and local pain (10%) the m

25 constipation (31 [36%]), fatigue (29 [33%]), myalgia 21 [24%]), and peripheral oedema 20 [23%]).

26 iarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]).

27 d included fever (85%), chills/sweats (54%), myalgias (38%), fatigue (31%), nausea/vomiting (31%), he

28 ucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%).

29 sms (13% v 1%), neutropenia (29% v 18%), and myalgia (5% v 0%).

30 of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs.

31 tions, including fever (96%), malaise (88%), myalgia (57%), cough (25%), and dizziness (14%).

32 stomatitis (9%), neurosensory changes (7%), myalgia (7%), and diarrhea (7%).

33 rol 70.4 +/- 0.7 years) and nine with statin myalgia (71.5 +/- 0.9 years).

34 ry neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (6%).

35 s (8%; three patients on seladelpar 200 mg), myalgia (8%; one patient on placebo and two on seladelpa

36 l features at presentation were fever (87%), myalgia (83%), skin (88%), renal (19%), severe gastroint

37 severe epidemics among ruminants and fever, myalgia, a hemorrhagic syndrome, and/or encephalitis in

38 o more likely to have a headache, dizziness, myalgias, abdominal pain, anorexia, leukopenia, lymphope

39 Myalgia (adjusted odds ratio [OR], 4.04; P = .02), hemor

40 be extended to patients with longer onset of myalgia after statin initiation.

41 biopsy obtained from a patient with chronic myalgia and arthralgia 6 months after acute SINV infecti

42 scle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal.

43 ose was associated with a lower incidence of myalgia and gastrointestinal (GI) disturbances than that

44 to distinguish from other conditions causing myalgia and may often lead to statin discontinuation.

45 Statins are associated with muscle myalgia and myopathy, which probably reduce habitual phy

46 grade 3 adverse events: one patient (2%) had myalgia and one patient (2%) had general physical health

47 eekly visual analogue scale (VAS) scores for myalgia and specific symptoms (VAS myalgia score and sym

48 The acute presentation was with malaise, myalgia and weakness, nausea and vomiting, and tender he

49 ases were defined as persons presenting with myalgia and/or periorbital edema and Trichinella-specifi

50 Myalgias and arthralgias of grades 1 to 2 occurred in 16

51 th NAGU exhibit nonspecific symptoms such as myalgias and fever, suggesting an infectious agent, but

52 One patient had myalgias and malaise after the first infliximab infusion

53 ient had a "flulike" illness associated with myalgias and malaise.

54 Myalgias and oral stomatitis were reported less frequent

55 (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chroni

56 rare event, most recent studies suggest that myalgias and relatively low-level muscle damage may occu

57 higher proportions of arthralgia, weakness, myalgia, and age 41-60 years.

58 ile categories except fluid retention, rash, myalgia, and anemia, which were more common at higher im

59 A febrile syndrome with fatigue, headache, myalgia, and arthralgia was highly associated with serop

60 teristic symptoms, including cutaneous rash, myalgia, and arthralgia, with the latter sometimes persi

61 Ts were neutropenia, stomatitis/pharyngitis, myalgia, and arthralgia.

62 me, diarrhea, hyperbilirubinemia, skin rash, myalgia, and arthralgia.

63 symptoms, including fever, headache, chills, myalgia, and arthralgia.

64 ents receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain.

65 eutropenia, fatigue, neuropathy, arthralgia, myalgia, and diarrhea.

66 luding rash, arthralgia, headache, pruritus, myalgia, and fever.

67 clinical presentations were fever, weakness, myalgia, and gastrointestinal symptoms.

68 rees F), cough, upper respiratory infection, myalgia, and headache were reported.

69 se events were injection-site pain, fatigue, myalgia, and headache.

70 endocrine dysregulation, fatigue, dysphoria, myalgia, and impaired mental and physical performance.

71 ause reactogenic side effects such as fever, myalgia, and injection site pain that have reduced their

72 ther tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included five (15.6%) patients

73 resented with acute renal failure, weakness, myalgia, and pigmented urine.

74 iorated LPS-induced fever, chills, headache, myalgia, and tachycardia (P<.01).

75 quiring statin treatment, who develop statin myalgia, and who cannot be satisfactorily treated with o

76 rred in 99 subjects (54 discontinuations, 49 myalgias, and 9 CK elevations).

77 nstitutional symptoms consisting of malaise, myalgias, and anorexia were the dose-limiting toxicities

78 nspecific prodrome of weakness, fatigue, and myalgias, and are at risk for ischemia-induced organ fai

79 as well tolerated with only low-grade fever, myalgias, and fatigue reported and 2 patients experienci

80 presented with 2 to 21 d of dyspnea, cough, myalgias, and fever.

81 His illness onset included malaise, myalgias, and low-grade fever.

82 ring loss, febrile neutropenia, hypotension, myalgias, and skin rash and were removed from treatment

83 ommonly either musculoskeletal (arthralgias, myalgias, and weakness) or pulmonary (cough, dyspnea, an

84 However, myalgias are much more common and limit their use in man

85 ore common with combination therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were m

86 More myalgia, arthralgia, edema, and febrile neutropenia occu

87 (14%), diarrhea (11%), nausea/vomiting (5%), myalgia/arthralgia (3%), and sensory neuropathy (3%).

88 ne grade 3 hypertriglyceridemia, two grade 3 myalgia/arthralgia, and one grade 3 fatigue.

89 The most frequent toxicities were myalgia/arthralgia, fatigue, and triglyceridemia.

90 istration and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%),

91 3.2, P = .16), they were less likely to have myalgias/arthralgias (P< .001) and vomiting (P = .02).

92 e degree of grade 2 constitutional symptoms (myalgias/arthralgias and fatigue) at 75 micrograms/kg, d

93 Grade III myalgias/arthralgias and headaches required dose reducti

94 Reversible grade 2 fatigue and myalgias/arthralgias were seen in all pts at 75 microgra

95 symptoms (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hy

96 Fever, myalgias/arthralgias, fatigue, nausea, and headaches wer

97 report anorexia, asthenia, diarrhea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at a

98 toxicities, such as cheilitis, headache, and myalgias/arthralgias, were mild or absent.

99 Myalgias at doses 0.2 mg/kg or greater were dose limitin

100 cterized by fever with chills, headache, and myalgias at the highest dose.

101 headache, malaise, fatigue, arthralgias, and myalgias) before randomization.

102 The principal toxicities were myalgias, bone pain, fever, nausea, and mild thrombocyto

103 least 37.6 degrees C, and most had headache, myalgias, chills, and varying combinations of leukopenia

104 including fever >/=37.8 degrees C, headache, myalgia, cough, sore throat, runny nose and sputum), pau

105 eletal muscle, causing exercise intolerance, myalgia, cramps, or fixed weakness, which often affects

106 were not different than control in terms of myalgia, creatine kinase elevation, cancer, and disconti

107 n monotherapy versus placebo; and reports of myalgia, creatine kinase elevations, rhabdomyolysis, tra

108 risk of transaminase elevations, but not of myalgias, creatine kinase elevations, rhabdomyolysis, or

109 matous, macular rash that, together with the myalgia, displays centrifugal migration.

110 for treatment-associated arthralgias and/or myalgias during 17 of 52 treatment courses.

111 dverse events include generalised oedema and myalgia (each in two [1%] patients) in those given pembr

112 1 were minimal; the most common were nausea, myalgias, edema, and diarrhea.

113 nts being fatigue (14 [30%]; all grade 1-2), myalgia (eight [17%]; all grade 1-2), and peripheral oed

114 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash.

115 ne (2%) grade 3 syncope and one (2%) grade 3 myalgia event in different cohorts.

116 These results suggest that the myalgia experienced by individuals with TRAPS is due to

117 s with symptoms of fibromyalgia (arthralgia, myalgia, fatigue) and oral and ocular dryness in the pre

118 ts develop a syndrome of diffuse arthralgia, myalgia, fatigue, and subjective cognitive difficulty du

119 (grade 4) toxicities including neutropenia, myalgia, fatigue, depression, and other neurologic toxic

120 gs was not possible, but fever and prominent myalgias favored influenza and prominent rhinorrhea favo

121 Side effects of interferon therapy include myalgias, fever, nausea, irritability, and depression.

122 with symptoms including fever, headache, and myalgia, followed by swelling of the salivary glands.

123 l presentations were characterised by fever, myalgia, headache, and confusion, followed by severe mul

124 Myalgia, headache, and fatigue were common.

125 0, and 50/50 groups, respectively; transient myalgia, headache, and fatigue were the commonest system

126 Fatigue, myalgia, headache, and injection site pain were the most

127 s presenting with acute febrile illness with myalgia, headache, neutropenia, thrombocytopenia, and el

128 degrees C, hypotension, rigors, arthralgias, myalgias, headache, and/or malaise.

129 is acute febrile illness is characterized by myalgias, headache, thrombocytopenia, and elevated serum

130 alaise in 13 (46%), dizziness in nine (32%), myalgia in four (14%), and chills in four (14%).

131 ive outbreaks of debilitating arthralgia and myalgia in human populations.

132 rates of transient local injection pain and myalgia in the 4CMenB group.

133 e of vague symptoms of dryness, fatigue, and myalgias in the general population.

134 systemic reactions (chills, arthralgias, and myalgias) in the vaccine group than in the placebo group

135 Markers of myalgia (intrusive body pain) and myopathy (self-reporte

136 Statin-related myalgia is difficult to distinguish from other condition

137 Myalgia is one of the most characteristic features of th

138 Clinical findings include fever, headache, myalgia, leukopenia, thrombocytopenia, and hepatic infla

139 n of both ehrlichioses with fever, headache, myalgias, leukopenia, thrombocytopenia, and elevated liv

140 Statins had little or no effect on cancer, myalgia, liver function, or withdrawal from treatment, a

141 symptoms (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizziness, metalli

142 SAMS is the most frequent SAS, and mild myalgia may affect 5% to 10% of statin users.

143 Rates of myalgia, muscle weakness, neuropsychiatric conditions, c

144 The presenting clinical features are myalgias, myoglobinuria, and an elevated serum creatine

145 multiple symptoms with minimal arthralgia or myalgia (n = 4, n = 14).

146 l illness (n = 54), fever (n = 47), and limb myalgia (n = 41).

147 = 1), nausea (n = 1), vomiting (n = 1), and myalgias (n = 1).

148 edema, n = 7; conjunctival injection, n = 7; myalgia, n = 1; all grade 1).

149 se events included fatigue, fever, headache, myalgia, nausea, and decreased appetite.

150 penia and leukopenia followed by neuropathy, myalgia, nausea, fatigue, headache, arthralgia, and vomi

151 atory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, an

152 he low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatm

153 = 3 neuropathy, neutropenia, arthralgia, and myalgia occurred in the nab-PC arm, and less thrombocyto

154 The variant was not associated with myalgia (odds ratio, 0.84; 95% confidence interval, 0.52

155 p; one patient had recurrence of fatigue and myalgia one year after CTL infusion.

156 (one [2%] person in the placebo group), and myalgia (one [2%] person in each group).

157 adverse events occurred in one patient each: myalgia (one [2%]), increased blast cell count (one [2%]

158 sented with such symptoms as fever (94%) and myalgia or arthralgia (78%).

159 icity included peripheral neuropathy in 57%, myalgia or arthralgia in 30%, neutropenia in 53%, neutro

160 EC-D reported significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and pe

161 ith high fever, chills, marked headache, and myalgia or arthralgia.

162 Progression of myalgia or myositis to rhabdomyolysis is rare (one in 30

163 mptom attributable to malaria, with fatigue, myalgias or arthralgias, headache, and chills most commo

164 of the muscle disorder may vary from trivial myalgias or elevations of creatine kinase in asymptomati

165 Chronic myalgias or other pain syndromes have not been confirmed

166 CAE) as discontinuation for any side effect, myalgia, or CK >3x upper limit of normal during follow-u

167 fever, headache, neck stiffness, arthralgia, myalgia, or fatigue.

168 headache, elevated temperature, arthralgias, myalgias, or fatigue, a larger number of macrophages and

169 everity showed a significant amelioration of myalgia (P = .003), headache (P = .025), and fatigue (P

170 Subjective fever (p<0.0001), myalgia (p=0.036), and chills (p=0.026) were significant

171 exposed individuals characterized by fever, myalgia, periorbital edema, and fatigue.

172 Bone pain, myalgia, presyncope, or fever occurred in 55% of patient

173 .8), history of eczema (mOR=3.4), fever with myalgia prior to illness (mOR=2.6), having tonsils (mOR=

174 A 67-year-old woman had fever, myalgias, progressive weakness, and respiratory insuffic

175 AEs, particularly fever, myalgias, pruritus, and proteinuria/hematuria, occurred

176 mans characterized by fever, polyarthralgia, myalgia, rash, and headache.

177 Fever, myalgia, rash, night sweats, and arthralgia occurred mor

178 s by which ischemic-like conditions generate myalgia remain unclear.

179 n significant absolute increases in risks of myalgias (risk difference/1000 patients [RD], 2.7; 95% C

180 se events (RR, 0.99 [95% CI, 0.94 to 1.04]), myalgias (RR, 0.96 [95% CI, 0.79 to 1.16]), or liver-rel

181 The primary outcome was the VAS myalgia score (range, 0 to 100 mm).

182 cores for myalgia and specific symptoms (VAS myalgia score and symptom-specific VAS score, respective

183 e seen between statin and placebo in the VAS myalgia score, symptom-specific VAS score, pain interfer

184 Symptoms included headache, fever, chills, myalgia, shortness of breath, and fatigue.

185 s (fever, anorexia, weight loss, fatigue and myalgias), signs of systemic inflammation (anemia, throm

186 s of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; some patients

187 lack of association between the variant and myalgia suggests that it cannot reliably be used as a bi

188 Eosinophilia-myalgia syndrome (EMS) is characterized by subacute onse

189 eosinophilic conditions such as eosinophilia-myalgia syndrome and idiopathic hypereosinophilic syndro

190 s, toxic oil syndrome in Spain, eosinophilia-myalgia syndrome from contaminated L-tryptophan, diethyl

191 neuropathy, are uncommon, and the arthralgia/myalgia syndrome was not observed.

192 r, these conditions include the eosinophilia-myalgia syndrome, epidemic toxic oil syndrome, eosinophi

193 ; and "isolated" polymyalgia rheumatica with myalgias, systemic inflammation, and subclinical vasculi

194 7% of patients may experience statin-induced myalgia that limits compliance with a treatment regimen.

195 strointestinal symptoms, chills, joint pain, myalgia, thrombocytopenia, leukocytopenia, and some hemo

196 h myotoxicity, which ranges in severity from myalgias to rhabdomyolysis resulting in renal failure an

197 ve myotoxic effects ranging in severity from myalgias to rhabdomyolysis.

198 nalyses, fluid retention, superficial edema, myalgia, vomiting, and rash were less frequent with dasa

199 Statin myalgia was associated with impaired muscle function, in

200 n multivariate logistic regression analysis, myalgia was less likely with HCoV infection than with LD

201 Myalgia was studied in JUPITER trial participants.

202 Generalized myalgia was the DLT.

203 Generalized myalgia was the dose-limiting toxicity (DLT) and occurre

204 Myalgia was the most common treatment-emergent adverse e

205 Thrombocytopenia, neuropathy, and myalgia were greater with paclitaxel 250 mg/m2 (P <.05).

206 Arthralgias and myalgia were reported significantly more often by conval

207 Myalgias were dose-related and cumulative, and often sta

208 At 8-month follow-up, fatigue, headache, and myalgias were persistent symptoms; gait and movement dis

209 ed patients with a history of statin-related myalgia whose symptoms are difficult to evaluate, n-of-1

210 mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weak

211 itis, AQP4-IgG seropositivity, and recurrent myalgias with hyperCKemia.

212 g travelers returning ill from Malaysia with myalgia, with or without fever, should consider AMS, not

213 e statin that was previously associated with myalgia within 3 weeks of open-label use versus matching

214 We hypothesised that statin myalgia would be allied to impaired strength and work ca